phrykt

Edgewise Therapeutics, Inc. (EWTX): who owns it and who trades it

As of Nov 16, 2026, EWTX insiders reported 33 open-market sales worth $17.6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alan J Russell (Director), with $8.1M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Edgewise Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns EWTX

225 funds and institutions reported EWTX shares worth $4.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Orbimed Advisors LLC with 14.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Orbimed Advisors LLC14.4%
Paradigm Biocapital Advisors LP9.5%
Ra Capital Management, L.P.7.8%
BlackRock, Inc.6.1%
Jupiter Topco LLC5.6%
FMR LLC (Fidelity)5.1%
Novo Holdings A/s5.0%
Driehaus Capital Management LLC4.4%
Perceptive Advisors LLC4.1%
Vanguard Capital Management LLC3.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Orbimed Advisors LLC15.52M14.42%$631MNo change
Paradigm Biocapital Advisors LP10.22M9.49%$415M+39%
Ra Capital Management, L.P.8.39M7.80%$341M-20%
BlackRock, Inc.6.61M6.14%$268M+2%
Jupiter Topco LLC6.08M5.65%$247M–
FMR LLC (Fidelity)5.49M5.10%$223M+440%
Novo Holdings A/s5.35M4.97%$217MNo change
Driehaus Capital Management LLC4.73M4.39%$192M+6%
Perceptive Advisors LLC4.37M4.07%$178M-1%
Vanguard Capital Management LLC3.86M3.59%$157M+2%
Baker Bros. Advisors LP3.70M3.44%$150M-44%
Siren, L.L.C.3.18M2.96%$129M-28%
California State Teachers Retirement System2.90M2.69%$71.3M+3846%
Cormorant Asset Management, LP2.51M2.33%$102M-23%
Geode Capital Management, LLC2.17M2.02%$88.3M+21%
Alliancebernstein L.P.2.12M1.97%$66.7M+23%
Integral Health Asset Management, LLC2.00M1.86%$81.3M+25%
Braidwell LP2.00M1.86%$81.1M-15%
Morgan Stanley1.95M1.81%$79.2M-13%
State Street Corp1.83M1.70%$74.3M+6%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, EWTX insiders reported $0 of open-market purchases and $17.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$17.6M
33 trades, 7 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 10, 2026

Purchases and sales by month

$7.9M$7.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026Michael NofiCFOSale4,442$45.43$202KForm 4
Aug 13, 2026Joanne M. DonovanCMOSale2,919$43.41$127KForm 4
Aug 12, 2026Joanne M. DonovanCMOSale800$44.52$35.6KForm 4
Aug 12, 2026Joanne M. DonovanCMOSale104$44.43$4.6KForm 4
Aug 12, 2026Joanne M. DonovanCMOSale2,779$43.71$121KForm 4
Aug 12, 2026Joanne M. DonovanCMOSale2,839$43.78$124KForm 4
Aug 12, 2026Alan J RussellDirectorSale3,238$43.68$141KForm 4
Aug 12, 2026Alan J RussellDirectorSale390$44.46$17.3KForm 4
Aug 12, 2026Alan J RussellDirectorSale2,273$43.68$99.3KForm 4
Aug 12, 2026John R MooreGeneral CounselSale2,439$43.81$107KForm 4
Aug 12, 2026John R MooreGeneral CounselSale59$44.41$2.6KForm 4
Aug 12, 2026John R MooreGeneral CounselSale99$44.50$4.4KForm 4
Aug 12, 2026John R MooreGeneral CounselSale2,419$43.80$106KForm 4
Aug 12, 2026Behrad DerakhshanChief Business OfficerSale150$44.44$6.7KForm 4
Aug 12, 2026Behrad DerakhshanChief Business OfficerSale2,475$43.70$108KForm 4
Aug 12, 2026Behrad DerakhshanChief Business OfficerSale304$44.50$13.5KForm 4
Aug 12, 2026Behrad DerakhshanChief Business OfficerSale2,171$43.79$95.1KForm 4
Aug 12, 2026Kevin KochCEOSale8,276$43.66$361KForm 4
Aug 12, 2026Kevin KochCEOSale8,782$43.64$383KForm 4
Aug 12, 2026Kevin KochCEOSale913$44.33$40.5KForm 4
Jul 1, 2026Alan J RussellDirectorSale69,648$39.41$2.7MForm 4
Jul 1, 2026Alan J RussellDirectorSale130,352$39.41$5.1MForm 4
May 5, 2026Joanne M. DonovanCMOSale50,000$38.57$1.9MForm 4
May 4, 2026Joanne M. DonovanCMOSale5,230$31.29$164KForm 4
Apr 1, 2026Joanne M. DonovanCMOSale28,662$32.31$926KForm 4
Mar 31, 2026Joanne M. DonovanCMOSale21,338$32.12$685KForm 4
Mar 27, 2026Joanne M. DonovanCMOSale9,623$30.98$298KForm 4
Mar 27, 2026Joanne M. DonovanCMOSale6,735$30.98$209KForm 4
Jan 21, 2026Badreddin EdrisDirectorSale13,690$29.44$403KForm 4
Jan 21, 2026Badreddin EdrisDirectorSale66,477$29.44$2MForm 4
Jan 21, 2026Badreddin EdrisDirectorSale10,463$29.44$308KForm 4
Jan 21, 2026Badreddin EdrisDirectorSale17,236$29.44$507KForm 4
Jan 21, 2026Badreddin EdrisDirectorSale7,605$29.44$224KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Alan J RussellChief Scientific Officer, Director–$8.1MAug 12, 2026
Joanne M. DonovanCMO–$4.6MAug 13, 2026
Badreddin EdrisDirector–$3.4MJan 21, 2026
Kevin KochPresident and CEO, Director–$785KAug 12, 2026
Behrad DerakhshanChief Business Officer–$223KAug 12, 2026
John R MooreGeneral Counsel–$220KAug 12, 2026
Michael NofiChief Financial Officer–$202KNov 10, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

EWTX short interest

High short interest. 11.7% of EWTX shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 23%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12.70M EWTX shares were sold short, 11.7% of the shares outstanding, up 8.0% from the report before. At the average daily volume of 1.32M shares, buying them all back would take about 9.6 trading days (days to cover).

Shares short, % of all shares

11.7%May 15Oct 3012.2%

Days to cover

9.6May 15Oct 3013.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612.70M11.69%+8%1.32M9.6
Oct 15, 202611.75M10.82%+5%1.39M8.5
Sep 30, 202611.22M10.34%+18%2.00M5.6
Sep 15, 20269.54M8.79%+2%1.19M8.0
Aug 31, 20269.35M8.61%-3%1.16M8.0
Aug 14, 20269.68M8.91%-2%1.51M6.4
Jul 31, 20269.84M9.06%-2%815,02412.1
Jul 15, 202610.07M9.36%-4%1.21M8.3
Jun 30, 202610.49M9.75%+6%2.08M5.0
Jun 15, 20269.93M9.23%-9%1.74M5.7
May 29, 202610.91M10.14%+5%982,74711.1
May 15, 202610.35M9.62%+2%1.48M7.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Edgewise Therapeutics company events

Edgewise Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jul 13, 2026DealEdgewise Therapeutics, Inc. completed the previously announced acquisition of the Company’s sevasemten compound and certain other related assets collectively constituting the Company’s muscular dystrophy program by Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, the “Buyers”… Filing
  4. Jun 5, 2026VoteReported shareholder vote results. Filing
  5. Jun 1, 2026AgreementEdgewise Therapeutics, Inc., announced its entry into an Asset Purchase Agreement with Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, the “Buyers”) on May 31, 2026. Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Feb 26, 2026ResultsReleased financial results. Filing
  8. Nov 20, 2025LeadershipThe Board of Directors of Edgewise Therapeutics, Inc. appointed Christopher Martin to serve as a Class I director, with a term expiring at the Company’s 2028 annual meeting of stockholders. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Edgewise Therapeutics financials

Famous investors that hold EWTX

3 of the 50 well-known investors we track reported holding EWTX in their latest 13F filing. The largest position is Ken Griffin's, worth $104M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20262.57M$104M0.1%+447%
Paul Tudor Jones · Tudor Investment CorpQ3 202658,531$2.4M0.0%+3%
Israel Englander · Millennium ManagementQ3 202633,479$1.4M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named EWTX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A6.7%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A6.7%
Nov 5, 2026FMR LLC13G/A0.9%
Nov 5, 2026FMR LLC13G/A0.9%

Questions about Edgewise Therapeutics, Inc. (EWTX) stock

Who owns the most EWTX stock?

The largest reported owner of Edgewise Therapeutics, Inc. (EWTX) is Orbimed Advisors LLC, with 14.4% of the company. In total, 225 funds and institutions reported holding EWTX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are EWTX insiders buying or selling?

In the last 12 months, EWTX insiders reported no open-market purchases and 33 sales worth $17.6M. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in EWTX?

As of Oct 30, 2026, 12.70M EWTX shares were sold short, 11.7% of the shares outstanding, up 8.0% from the report before. At the average daily volume of 1.32M shares, buying them all back would take about 9.6 trading days (days to cover). See the history.

Which famous investors hold EWTX?

3 of the 50 well-known investors we track reported EWTX in their latest 13F filing, including Ken Griffin, Paul Tudor Jones, Israel Englander. The largest position is worth $104M. See all holders.

Executive pay

Edgewise Therapeutics's chief executive was paid a total of $7.4M for the year ended Dec 31, 2025, down 3% from $7.6M the year before. In the last 12 months, Edgewise Therapeutics's executives and directors bought no stock on the open market and sold $17.6M.

Chief executive, total pay$7.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$7.9MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.